For additional information regarding Universal Biosensors, refer to:http://www.universalbiosensors.com. Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests forpoint-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.
Company profile
Ticker
UVBIF
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Universal Biosensors Pty Ltd. • Hemostasis Reference Laboratory Inc. • Universal Biosensors B.V. • Universal Biosensors LLC ...
IRS number
980424072
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
12 Apr 24
8-K
Entry into a Material Definitive Agreement
11 Apr 24
DEF 14A
Definitive proxy
8 Apr 24
8-K
Unregistered Sales of Equity Securities
29 Mar 24
DEF 14A
Definitive proxy
25 Mar 24
PRE 14A
Preliminary proxy
15 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
15 Mar 24
DEFA14A
Additional proxy soliciting materials
5 Mar 24
8-K
Entry into a Material Definitive Agreement
5 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
Latest ownership filings
4
Craig E. Coleman
26 Mar 24
4
John Stewart Sharman
25 Mar 24
4
Salesh Balak
28 Feb 24
4
Graham A McLean
11 Dec 23
4
Craig E. Coleman
13 Sep 23
4
David L Hoey
21 Aug 23
4
Salesh Balak
27 Apr 23
4
Graham A McLean
15 Mar 23
SC 13G
Richmond Hill Capital Pty Ltd
17 Jan 23
4
John Stewart Sharman
3 Jan 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 16.64 mm | 16.64 mm | 16.64 mm | 16.64 mm | 16.64 mm | 16.64 mm |
Cash burn (monthly) | 955.00 | 975.84 k | 1.25 mm | 2.56 mm | (no burn) | 820.15 k |
Cash used (since last report) | 6.54 k | 6.68 mm | 8.57 mm | 17.49 mm | n/a | 5.61 mm |
Cash remaining | 16.63 mm | 9.96 mm | 8.07 mm | -847.55 k | n/a | 11.03 mm |
Runway (months of cash) | 17418.3 | 10.2 | 6.4 | -0.3 | n/a | 13.4 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | John Stewart Sharman | Common Stock | Option exercise | Acquire M | No | No | 0.2 | 1,364,666 | 272.93 k | 1,444,666 |
25 Mar 24 | John Stewart Sharman | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.2 | 1,364,666 | 272.93 k | 0 |
25 Mar 24 | Coleman Craig E. | Common Stock | Buy | Acquire P | Yes | No | 0.2 | 1,000,000 | 200.00 k | 56,798,601 |
27 Feb 24 | Salesh Balak | Stock Option Common Stock | Other | Dispose J | No | No | 0.5 | 216,300 | 108.15 k | 0 |
11 Dec 23 | Graham A McLean | Common Stock | Grant | Acquire A | Yes | No | 0.1987 | 75,000 | 14.90 k | 625,000 |
11 Sep 23 | Coleman Craig E. | Common Stock | Buy | Acquire P | Yes | No | 0.22 | 100,000 | 22.00 k | 753,620 |